Cellyan Biotechnology Co., Ltd (HKPD) company profile
Close on Nov 17, 2026Market cap $24.93MP/E –Yield –
About Cellyan Biotechnology
Wholesale-Drugs, Proprietaries & Druggists' Sundries, SIC 5122
Cellyan Biotechnology Co., Ltd. operates in the supply chain services and over-the-counter pharmaceutical sectors. Through its Supply Chain Services division, the company provides logistics solutions and cross-border procurement and distribution of over-the-counter pharmaceutical products. It engages with partners across the broader logistics industry, serving commercial merchants, consumers, and large logistics providers requiring specialized pharmaceutical distribution expertise.
The company conducts substantially all of its operations in Hong Kong, where it maintains warehousing, logistics, and packaging networks supported by third-party suppliers and logistics subcontractors. Cellyan Biotechnology is an exempted holding company incorporated in the Cayman Islands, with its principal executive offices located in Kowloon, Hong Kong.
Summary of the business section of Cellyan Biotechnology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cellyan Biotechnology Co., Ltd
- Headquarters
- Kowloon, Hong Kong
- Address
- Room B1, 5/F. Well Town Ind. Building, 13 Ko Fai Road, Yau Tong
- Phone
- (852) 26189289
- Website
- 9zt.hk
- Employees
- 2, Mar 31, 2026
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Incorporated in
- E9
- Fiscal year ends
- March 31
- Auditor
- ONESTOP ASSURANCE PAC, Singapore
Stock & identifiers
- Ticker
- HKPD
- Exchange
- Nasdaq
- IPO date
- Jan 15, 2025
- Shares outstanding
- 16M, Mar 31, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 2007702
- CUSIP
- G6365B104
- FIGI
- BBG01QK91KR4
- Share class FIGI
- BBG01QK91LS1
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Chenyu Andy Liang | CEO and Director | – |
| Zifeng Wang | Chief Strategy Officer | – |
| Shu Liu | CFO | – |
| Kam Leung CHAN | Director | – |
| Lap Sun Wong | Director | 18,468 |
| Jingyan Wu | Director | – |
| Mike Yao Zhou | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 15, 2025
- Exchange
- Nasdaq
- First trading day
- Jan 15, 2025
- First-day close
- $2.82
- Lock-up ends (est.)
- Jul 14, 2025
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We have two employee directors, Mr.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 31, 2026 | Late filing | Notification of late filing |
| Dec 17, 2025 | Name change | Name changed from Hong Kong Pharma Digital Technology Holdings Ltd to Cellyan Biotechnology Co., Ltd |
| Jul 31, 2025 | Late filing | Notification of late filing |
| Jan 15, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 8, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?